Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.
|Articles|July 9, 2015
Parexel Expands Model-Based Drug Development Offering
Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.
Advertisement
Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group. The Parexel QCD leverages mathematical models for a quantitative analysis of the relationship between drugs, disease and patients, modeling and simulation can predict a drug’s benefits and adverse effects in a patient population prior to conducting a clinical trial. MBDD can improve the efficiency of clinical development by providing quantitative justification for trial design, dose selection, and decisions during trial execution.
Advertisement
Related to this article
ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than feature checklists.
ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another login to juggle.
Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development.
Sequoia’s Dan White and Dr. Tom Kreamer touch on why sponsors and CROs should treat a site network as one centralized partnerto speed startup timelines and strengthen execution.
Sequoia Clinical Research’s CEO Dan White and CMO, Dr. Tom Kreamer explain what it takes to merge three site organizations into one network.
Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building infrastructure at the actual point of care.
Trially CEO Kyle McAllister explains why transparent AI reasoning is essential for trial patient matching.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What It Actually Means to Embed AI Across the Clinical Operating Model
2
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
3
2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?
4
2026 SCRS Global Site Solutions Summit: What Does Al-Assisted Patient Matching Look Like?
5